Increase in adiponectin levels during pioglitazone therapy in relation to glucose control, insulin resistance as well as ghrelin and resistin levels

Journal of Endocrinological Investigation

Volumn 29, Issue 3, 2006, Pages 231-236

  Otto, Carsten ^a   Otto, B ^a   Goke B ^a   Pfeiffer, A F H ^b,d   Lehrke, M ^a,c   Vogeser, M ^a   Spranger, J ^b,d   Parhofer, K G ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Glitazone; Insulin resistance; Insulin sensitizer; PPAR; Type 2 diabetes

Indexed keywords

ADIPONECTIN; GHRELIN; GLIBENCLAMIDE; GLIMEPIRIDE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PIOGLITAZONE; RESISTIN; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE DURATION; DRUG DOSE REGIMEN; ENZYME LINKED IMMUNOSORBENT ASSAY; GLUCOSE BLOOD LEVEL; HOMEOSTASIS; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; RADIOIMMUNOASSAY;

EID: 33646250674     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345545     Document Type: Article

References (28)

1. Nakano Y, Tobe T, Choi-Miura NH, Mazda T, TomitaT. Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem 1996, 120: 803-12.
2. Spranger J, Kroke A, Möhlig M, et al. Adiponectin and protection against type 2 diabetes mellitus. Lancet 2003, 361: 226-8.
3. Pischon T, Girman CJ, Hotamisligil GS, Rifai N, Hu FB, Rimm EB. Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291: 1730-7.
4. Dormandy JA, Charbonnel B, Eckland DJA, et al. Secondary prevention of macrovasular events in patients with type 2 diabetes in the PROactive Study (prospective pioglitazone clinical trial in macrovascular events): a randomized controlled trial. Lancet 2005, 366: 1279-89.
5. Marx N, Froehlich J, Siam L, et al. Antidiabetic PPAR gamma-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease. Arterioscler Thromb Vasc Biol 2003, 23: 283-8.
6. Satoh N, Ogawa Y, Usui T, et al. Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 2003, 26: 2493-9.
7. Maeda N, Takahashi M, Funahashi T, et al. PPARγ ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 2001, 50: 2094-9.
8. Yang WS, Jeng CY, Wu TJ, et al. Synthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin in type 2 diabetic patients. Diabetes Care 2002, 25: 376-80.
9. Steppan CM, Balley ST, Bhat S, et al. The hormone resistin links obesity to diabetes. Nature 2001, 409: 307-12.
10. Ott V, Fasshauer M, Dalski A, et al. Direct peripheral effects of ghrelin include suppression of adiponectin expression. Horm Metab Res 2002, 34: 640-5.
11. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28: 412-19.
12. Parhofer KG, Otto C, Geiss HC, Laubach E, Göke B. Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - results of a pilot study. Exp Clin Endocrinol Metab 2005, 113: 49-52.
13. Berg AH, Combs TP, Du X, Brownlee M, Scherer P. The adipocyte-secreted protein ACRP30 enhances hepatic insulin action. Nature Med 2001, 7: 947-53.
14. Ouchi N, Kihara S, Arita Y, et al. Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 2001, 103: 1057-63.
15. Kondo H, Shimomura I, Matsukawa Y, et al. Association of adiponectin mutation with type 2 diabetes: a candidate gene for the insulin resistance syndrome. Diabetes 2002, 51: 2325-8.
16. Tonelli J, Li W, Kishore P, et al. Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 2004, 53: 1621-9.
17. Yu JG, Javorschi S, Hevener AL, et al. The effect of thiazolidinediones on plasma adiponectin levels in normal, obese, and type 2 diabetic subjects. Diabetes 2002, 51: 2968-74.
18. Iwaki M, Matsuda M, Maeda N, et al. Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 2003, 52: 1655-63.
19. Fasshauer M, Klein J, Neumann S, Eszlinger M, Paschke R. Hormonal regulation of adiponectin gene expression in 3T3-L1 adipocytes. Biochem Biophys Res Comm 2002, 290: 1084-9.
20. Möhlig M, Wegewitz U, Osterhoff M, et al. Insulin decreases human adiponectin plasma levels. Horm Metab Res 2002, 34: 655-8.
21. Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA, Ukkola O. Low plasma ghrelin is associated with insulin resistance, hypertension, and the prevalence of type 2 diabetes. Diabetes 2003, 52: 2546-53.
22. Purnell JQ, Weigle DS, Breen P, Cummings DE. Ghrelin levels correlate with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab 2003, 88: 5747-52.
23. McLaughlin T, Abbasi F, Lamendola C, Frayo RS, Cummings DE. Plasma ghrelin concentrations are decreased in insulin-resistant obese adults relative to equally obese insulin sensitive controls. J Clin Endocrin Metab 2004, 89: 1630-5.
24. Akamizu T, Shinomiya T, Irako T, et al. Separate measurement of plasma levels of acylated and desacyl ghrelin in healthy subjects using a new direct ELISA assay. J Clin Endocrin Metab 2005, 90: 6-9
25. Bajaj M, Suraamornkul S, Hardies LJ, Pratipanawatr T, DeFronzo RA. Plasma resistin concentration, hepatic fat content, and hepatic and peripheral insulin resistance in pioglitazone-treated type II diabetic patients. Int J Obes 2004, 28: 783-9.
26. Song H, Shojima N, Sakoda H, et al. Resistin is regulated by C/EBPs, PPARs, and signal-transducing molecules. Biochem Biophys Res Commun 2002, 299: 291-8.
27. Fukuen S, Iwaki M, Yasui A, Makishima M, Matsuda M, Shimimura I. Sulfonylurea agents exhibit peroxisome proliferator-activated receptor gamma agonistic activity. J Biol Chem 2005, 260: 23653-9.
28. Pajvani UB, Hawkins M, Combs TP, et al. Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 2004, 279: 12152-62.